nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Procarbazine—hematologic cancer	0.326	0.435	CbGbCtD
Deferoxamine—XDH—Daunorubicin—hematologic cancer	0.175	0.233	CbGbCtD
Deferoxamine—XDH—Mercaptopurine—hematologic cancer	0.135	0.18	CbGbCtD
Deferoxamine—XDH—Cisplatin—hematologic cancer	0.0681	0.0909	CbGbCtD
Deferoxamine—XDH—Doxorubicin—hematologic cancer	0.0456	0.0609	CbGbCtD
Deferoxamine—XDH—Purine metabolism—GMPS—hematologic cancer	0.00125	0.148	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—DCK—hematologic cancer	0.000997	0.118	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—GMPS—hematologic cancer	0.000627	0.0742	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—DCK—hematologic cancer	0.000501	0.0593	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—CDA—hematologic cancer	0.000435	0.0514	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PRDX2—hematologic cancer	0.000367	0.0434	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NQO1—hematologic cancer	0.00036	0.0426	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—SOD2—hematologic cancer	0.000277	0.0328	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—TXN—hematologic cancer	0.00026	0.0308	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—TXN—hematologic cancer	0.000236	0.028	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—MAPK14—hematologic cancer	0.000221	0.0262	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ALOX5—hematologic cancer	0.000211	0.0249	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—FOS—hematologic cancer	0.000195	0.0231	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTR—hematologic cancer	0.000193	0.0228	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MPO—hematologic cancer	0.000187	0.0221	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—hematologic cancer	0.000117	0.0139	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—MTHFR—hematologic cancer	0.000103	0.0122	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—CRP—hematologic cancer	9.81e-05	0.0116	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ICAM1—hematologic cancer	9.02e-05	0.0107	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—CCL2—hematologic cancer	8.07e-05	0.00955	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ALB—hematologic cancer	7.52e-05	0.0089	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IFNG—hematologic cancer	6.86e-05	0.00812	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—IL1B—hematologic cancer	6.12e-05	0.00724	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—FTCD—hematologic cancer	5.69e-05	0.00674	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PHYH—hematologic cancer	5.69e-05	0.00674	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GMPS—hematologic cancer	5.69e-05	0.00674	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SMPD3—hematologic cancer	5.21e-05	0.00616	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—DCK—hematologic cancer	4.55e-05	0.00539	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ASNS—hematologic cancer	4.55e-05	0.00539	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—B3GAT1—hematologic cancer	4.55e-05	0.00539	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—TNF—hematologic cancer	4.44e-05	0.00526	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HDC—hematologic cancer	4.32e-05	0.00511	CbGpPWpGaD
Deferoxamine—Oedema—Betamethasone—hematologic cancer	4.29e-05	0.000177	CcSEcCtD
Deferoxamine—Diarrhoea—Irinotecan—hematologic cancer	4.29e-05	0.000177	CcSEcCtD
Deferoxamine—Diarrhoea—Mitoxantrone—hematologic cancer	4.29e-05	0.000177	CcSEcCtD
Deferoxamine—Vomiting—Carmustine—hematologic cancer	4.29e-05	0.000177	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—hematologic cancer	4.26e-05	0.000176	CcSEcCtD
Deferoxamine—Infection—Dexamethasone—hematologic cancer	4.26e-05	0.000176	CcSEcCtD
Deferoxamine—Infection—Betamethasone—hematologic cancer	4.26e-05	0.000176	CcSEcCtD
Deferoxamine—Dizziness—Vincristine—hematologic cancer	4.26e-05	0.000175	CcSEcCtD
Deferoxamine—Vomiting—Alitretinoin—hematologic cancer	4.25e-05	0.000175	CcSEcCtD
Deferoxamine—Paraesthesia—Triamcinolone—hematologic cancer	4.25e-05	0.000175	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—hematologic cancer	4.24e-05	0.000175	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—hematologic cancer	4.24e-05	0.000175	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—hematologic cancer	4.24e-05	0.000175	CcSEcCtD
Deferoxamine—Headache—Carmustine—hematologic cancer	4.22e-05	0.000174	CcSEcCtD
Deferoxamine—Shock—Betamethasone—hematologic cancer	4.22e-05	0.000174	CcSEcCtD
Deferoxamine—Shock—Dexamethasone—hematologic cancer	4.22e-05	0.000174	CcSEcCtD
Deferoxamine—Dyspnoea—Triamcinolone—hematologic cancer	4.22e-05	0.000174	CcSEcCtD
Deferoxamine—Nervous system disorder—Betamethasone—hematologic cancer	4.21e-05	0.000174	CcSEcCtD
Deferoxamine—Nervous system disorder—Dexamethasone—hematologic cancer	4.21e-05	0.000174	CcSEcCtD
Deferoxamine—Thrombocytopenia—Betamethasone—hematologic cancer	4.2e-05	0.000173	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dexamethasone—hematologic cancer	4.2e-05	0.000173	CcSEcCtD
Deferoxamine—Vomiting—Ifosfamide—hematologic cancer	4.2e-05	0.000173	CcSEcCtD
Deferoxamine—Hypersensitivity—Cisplatin—hematologic cancer	4.19e-05	0.000173	CcSEcCtD
Deferoxamine—Tachycardia—Dexamethasone—hematologic cancer	4.19e-05	0.000173	CcSEcCtD
Deferoxamine—Tachycardia—Betamethasone—hematologic cancer	4.19e-05	0.000173	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—hematologic cancer	4.19e-05	0.000173	CcSEcCtD
Deferoxamine—Headache—Alitretinoin—hematologic cancer	4.18e-05	0.000173	CcSEcCtD
Deferoxamine—Angioedema—Prednisone—hematologic cancer	4.18e-05	0.000172	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—hematologic cancer	4.18e-05	0.000172	CcSEcCtD
Deferoxamine—Nausea—Thalidomide—hematologic cancer	4.17e-05	0.000172	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—hematologic cancer	4.17e-05	0.000172	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—hematologic cancer	4.16e-05	0.000171	CcSEcCtD
Deferoxamine—Dizziness—Irinotecan—hematologic cancer	4.14e-05	0.000171	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—hematologic cancer	4.14e-05	0.000171	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—hematologic cancer	4.12e-05	0.00017	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—hematologic cancer	4.12e-05	0.00017	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—hematologic cancer	4.11e-05	0.000169	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—hematologic cancer	4.1e-05	0.000169	CcSEcCtD
Deferoxamine—Vomiting—Vincristine—hematologic cancer	4.09e-05	0.000169	CcSEcCtD
Deferoxamine—Urticaria—Prednisolone—hematologic cancer	4.09e-05	0.000168	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—hematologic cancer	4.06e-05	0.000168	CcSEcCtD
Deferoxamine—Pain—Triamcinolone—hematologic cancer	4.04e-05	0.000167	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—hematologic cancer	4.04e-05	0.000167	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—hematologic cancer	4.03e-05	0.000166	CcSEcCtD
Deferoxamine—Headache—Vincristine—hematologic cancer	4.03e-05	0.000166	CcSEcCtD
Deferoxamine—Hypotension—Betamethasone—hematologic cancer	4.01e-05	0.000165	CcSEcCtD
Deferoxamine—Hypotension—Dexamethasone—hematologic cancer	4.01e-05	0.000165	CcSEcCtD
Deferoxamine—Nausea—Carmustine—hematologic cancer	4e-05	0.000165	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—hematologic cancer	3.99e-05	0.000164	CcSEcCtD
Deferoxamine—Vomiting—Irinotecan—hematologic cancer	3.99e-05	0.000164	CcSEcCtD
Deferoxamine—Vomiting—Mitoxantrone—hematologic cancer	3.99e-05	0.000164	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—hematologic cancer	3.97e-05	0.000164	CcSEcCtD
Deferoxamine—Nausea—Alitretinoin—hematologic cancer	3.97e-05	0.000164	CcSEcCtD
Deferoxamine—Convulsion—Prednisone—hematologic cancer	3.97e-05	0.000164	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—hematologic cancer	3.96e-05	0.000163	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—hematologic cancer	3.96e-05	0.000163	CcSEcCtD
Deferoxamine—XDH—Metabolism—CDA—hematologic cancer	3.95e-05	0.00467	CbGpPWpGaD
Deferoxamine—Headache—Mitoxantrone—hematologic cancer	3.93e-05	0.000162	CcSEcCtD
Deferoxamine—Headache—Irinotecan—hematologic cancer	3.93e-05	0.000162	CcSEcCtD
Deferoxamine—Nausea—Ifosfamide—hematologic cancer	3.92e-05	0.000162	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	3.91e-05	0.000161	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	3.91e-05	0.000161	CcSEcCtD
Deferoxamine—Arthralgia—Prednisone—hematologic cancer	3.9e-05	0.000161	CcSEcCtD
Deferoxamine—Myalgia—Prednisone—hematologic cancer	3.9e-05	0.000161	CcSEcCtD
Deferoxamine—Diarrhoea—Cisplatin—hematologic cancer	3.89e-05	0.000161	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—hematologic cancer	3.88e-05	0.00016	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—hematologic cancer	3.87e-05	0.00016	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	3.87e-05	0.00016	CcSEcCtD
Deferoxamine—Paraesthesia—Dexamethasone—hematologic cancer	3.85e-05	0.000159	CcSEcCtD
Deferoxamine—Paraesthesia—Betamethasone—hematologic cancer	3.85e-05	0.000159	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—hematologic cancer	3.84e-05	0.000159	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—hematologic cancer	3.84e-05	0.000158	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—hematologic cancer	3.84e-05	0.000158	CcSEcCtD
Deferoxamine—Erythema—Methotrexate—hematologic cancer	3.83e-05	0.000158	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—hematologic cancer	3.82e-05	0.000158	CcSEcCtD
Deferoxamine—Nausea—Vincristine—hematologic cancer	3.82e-05	0.000158	CcSEcCtD
Deferoxamine—XDH—Metabolism—PC—hematologic cancer	3.8e-05	0.0045	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Prednisolone—hematologic cancer	3.79e-05	0.000156	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—hematologic cancer	3.76e-05	0.000155	CcSEcCtD
Deferoxamine—Urticaria—Triamcinolone—hematologic cancer	3.76e-05	0.000155	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—hematologic cancer	3.74e-05	0.000154	CcSEcCtD
Deferoxamine—Body temperature increased—Triamcinolone—hematologic cancer	3.74e-05	0.000154	CcSEcCtD
Deferoxamine—Oedema—Prednisone—hematologic cancer	3.74e-05	0.000154	CcSEcCtD
Deferoxamine—Anaphylactic shock—Prednisone—hematologic cancer	3.74e-05	0.000154	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—hematologic cancer	3.73e-05	0.000154	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—hematologic cancer	3.73e-05	0.000154	CcSEcCtD
Deferoxamine—Nausea—Mitoxantrone—hematologic cancer	3.72e-05	0.000154	CcSEcCtD
Deferoxamine—Nausea—Irinotecan—hematologic cancer	3.72e-05	0.000154	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—hematologic cancer	3.72e-05	0.000153	CcSEcCtD
Deferoxamine—Infection—Prednisone—hematologic cancer	3.71e-05	0.000153	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—hematologic cancer	3.71e-05	0.000153	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Betamethasone—hematologic cancer	3.7e-05	0.000153	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	3.7e-05	0.000153	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—hematologic cancer	3.69e-05	0.000152	CcSEcCtD
Deferoxamine—Shock—Prednisone—hematologic cancer	3.68e-05	0.000152	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—hematologic cancer	3.67e-05	0.000152	CcSEcCtD
Deferoxamine—XDH—Metabolism—SLC35B2—hematologic cancer	3.67e-05	0.00434	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GBA—hematologic cancer	3.67e-05	0.00434	CbGpPWpGaD
Deferoxamine—Pain—Dexamethasone—hematologic cancer	3.67e-05	0.000151	CcSEcCtD
Deferoxamine—Pain—Betamethasone—hematologic cancer	3.67e-05	0.000151	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—hematologic cancer	3.67e-05	0.000151	CcSEcCtD
Deferoxamine—Nervous system disorder—Prednisone—hematologic cancer	3.66e-05	0.000151	CcSEcCtD
Deferoxamine—Tachycardia—Prednisone—hematologic cancer	3.65e-05	0.00015	CcSEcCtD
Deferoxamine—Skin disorder—Prednisone—hematologic cancer	3.63e-05	0.00015	CcSEcCtD
Deferoxamine—Nausea—Gemcitabine—hematologic cancer	3.63e-05	0.00015	CcSEcCtD
Deferoxamine—Vomiting—Cisplatin—hematologic cancer	3.62e-05	0.000149	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—hematologic cancer	3.61e-05	0.000149	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—hematologic cancer	3.59e-05	0.00424	CbGpPWpGaD
Deferoxamine—Erythema—Epirubicin—hematologic cancer	3.58e-05	0.000148	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—hematologic cancer	3.57e-05	0.000147	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—hematologic cancer	3.56e-05	0.000147	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—hematologic cancer	3.55e-05	0.000146	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Betamethasone—hematologic cancer	3.51e-05	0.000145	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dexamethasone—hematologic cancer	3.51e-05	0.000145	CcSEcCtD
Deferoxamine—Hypersensitivity—Triamcinolone—hematologic cancer	3.48e-05	0.000144	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—hematologic cancer	3.45e-05	0.000142	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—hematologic cancer	3.45e-05	0.000142	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—hematologic cancer	3.44e-05	0.000142	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—hematologic cancer	3.44e-05	0.000142	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—hematologic cancer	3.43e-05	0.000141	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—hematologic cancer	3.43e-05	0.000141	CcSEcCtD
Deferoxamine—Urticaria—Dexamethasone—hematologic cancer	3.41e-05	0.000141	CcSEcCtD
Deferoxamine—Urticaria—Betamethasone—hematologic cancer	3.41e-05	0.000141	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Prednisone—hematologic cancer	3.4e-05	0.00014	CcSEcCtD
Deferoxamine—Dizziness—Prednisolone—hematologic cancer	3.4e-05	0.00014	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—hematologic cancer	3.4e-05	0.00014	CcSEcCtD
Deferoxamine—Body temperature increased—Dexamethasone—hematologic cancer	3.39e-05	0.00014	CcSEcCtD
Deferoxamine—Abdominal pain—Dexamethasone—hematologic cancer	3.39e-05	0.00014	CcSEcCtD
Deferoxamine—Abdominal pain—Betamethasone—hematologic cancer	3.39e-05	0.00014	CcSEcCtD
Deferoxamine—Body temperature increased—Betamethasone—hematologic cancer	3.39e-05	0.00014	CcSEcCtD
Deferoxamine—Nausea—Cisplatin—hematologic cancer	3.38e-05	0.000139	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—hematologic cancer	3.37e-05	0.000139	CcSEcCtD
Deferoxamine—XDH—Metabolism—MTAP—hematologic cancer	3.36e-05	0.00397	CbGpPWpGaD
Deferoxamine—Paraesthesia—Prednisone—hematologic cancer	3.36e-05	0.000138	CcSEcCtD
Deferoxamine—Pruritus—Triamcinolone—hematologic cancer	3.35e-05	0.000138	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—hematologic cancer	3.32e-05	0.000137	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—hematologic cancer	3.31e-05	0.000137	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—hematologic cancer	3.31e-05	0.000137	CcSEcCtD
Deferoxamine—Headache—Etoposide—hematologic cancer	3.27e-05	0.000135	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—hematologic cancer	3.26e-05	0.000134	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—hematologic cancer	3.26e-05	0.000134	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	3.24e-05	0.000133	CcSEcCtD
Deferoxamine—Headache—Prednisolone—hematologic cancer	3.22e-05	0.000133	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—hematologic cancer	3.21e-05	0.000132	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—hematologic cancer	3.19e-05	0.000131	CcSEcCtD
Deferoxamine—Dizziness—Triamcinolone—hematologic cancer	3.13e-05	0.000129	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—hematologic cancer	3.12e-05	0.000129	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—hematologic cancer	3.12e-05	0.000129	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—hematologic cancer	3.1e-05	0.000128	CcSEcCtD
Deferoxamine—Infection—Methotrexate—hematologic cancer	3.1e-05	0.000128	CcSEcCtD
Deferoxamine—Nausea—Etoposide—hematologic cancer	3.1e-05	0.000128	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—hematologic cancer	3.06e-05	0.000126	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—hematologic cancer	3.06e-05	0.000126	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Prednisone—hematologic cancer	3.06e-05	0.000126	CcSEcCtD
Deferoxamine—Nausea—Prednisolone—hematologic cancer	3.05e-05	0.000126	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—hematologic cancer	3.05e-05	0.000126	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—hematologic cancer	3.05e-05	0.000126	CcSEcCtD
Deferoxamine—Pruritus—Dexamethasone—hematologic cancer	3.04e-05	0.000125	CcSEcCtD
Deferoxamine—Pruritus—Betamethasone—hematologic cancer	3.04e-05	0.000125	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—hematologic cancer	3.03e-05	0.000125	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	3.03e-05	0.000125	CcSEcCtD
Deferoxamine—Vomiting—Triamcinolone—hematologic cancer	3.01e-05	0.000124	CcSEcCtD
Deferoxamine—XDH—Metabolism—FHL2—hematologic cancer	2.99e-05	0.00354	CbGpPWpGaD
Deferoxamine—Urticaria—Prednisone—hematologic cancer	2.97e-05	0.000122	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—hematologic cancer	2.97e-05	0.000122	CcSEcCtD
Deferoxamine—Headache—Triamcinolone—hematologic cancer	2.96e-05	0.000122	CcSEcCtD
Deferoxamine—Body temperature increased—Prednisone—hematologic cancer	2.95e-05	0.000122	CcSEcCtD
Deferoxamine—Abdominal pain—Prednisone—hematologic cancer	2.95e-05	0.000122	CcSEcCtD
Deferoxamine—Diarrhoea—Betamethasone—hematologic cancer	2.94e-05	0.000121	CcSEcCtD
Deferoxamine—Diarrhoea—Dexamethasone—hematologic cancer	2.94e-05	0.000121	CcSEcCtD
Deferoxamine—XDH—Metabolism—AGRN—hematologic cancer	2.93e-05	0.00347	CbGpPWpGaD
Deferoxamine—Anaphylactic shock—Epirubicin—hematologic cancer	2.92e-05	0.000121	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—hematologic cancer	2.92e-05	0.000121	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—hematologic cancer	2.92e-05	0.00012	CcSEcCtD
Deferoxamine—Infection—Epirubicin—hematologic cancer	2.9e-05	0.00012	CcSEcCtD
Deferoxamine—Shock—Epirubicin—hematologic cancer	2.88e-05	0.000119	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—hematologic cancer	2.87e-05	0.000118	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—hematologic cancer	2.87e-05	0.000118	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—hematologic cancer	2.86e-05	0.000118	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—hematologic cancer	2.85e-05	0.000118	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.85e-05	0.000117	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—hematologic cancer	2.84e-05	0.000117	CcSEcCtD
Deferoxamine—Dizziness—Dexamethasone—hematologic cancer	2.84e-05	0.000117	CcSEcCtD
Deferoxamine—Dizziness—Betamethasone—hematologic cancer	2.84e-05	0.000117	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—hematologic cancer	2.82e-05	0.000116	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—hematologic cancer	2.82e-05	0.000116	CcSEcCtD
Deferoxamine—Nausea—Triamcinolone—hematologic cancer	2.81e-05	0.000116	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—hematologic cancer	2.8e-05	0.000116	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.8e-05	0.000116	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—hematologic cancer	2.78e-05	0.000115	CcSEcCtD
Deferoxamine—XDH—Metabolism—HMMR—hematologic cancer	2.78e-05	0.00329	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—IDH2—hematologic cancer	2.78e-05	0.00329	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Prednisone—hematologic cancer	2.75e-05	0.000114	CcSEcCtD
Deferoxamine—Hypotension—Epirubicin—hematologic cancer	2.73e-05	0.000113	CcSEcCtD
Deferoxamine—Vomiting—Dexamethasone—hematologic cancer	2.73e-05	0.000112	CcSEcCtD
Deferoxamine—Vomiting—Betamethasone—hematologic cancer	2.73e-05	0.000112	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—hematologic cancer	2.7e-05	0.000111	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—hematologic cancer	2.7e-05	0.000111	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.7e-05	0.000111	CcSEcCtD
Deferoxamine—Headache—Dexamethasone—hematologic cancer	2.69e-05	0.000111	CcSEcCtD
Deferoxamine—Headache—Betamethasone—hematologic cancer	2.69e-05	0.000111	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—hematologic cancer	2.69e-05	0.000111	CcSEcCtD
Deferoxamine—Pain—Methotrexate—hematologic cancer	2.67e-05	0.00011	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.66e-05	0.00011	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—hematologic cancer	2.66e-05	0.00011	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—hematologic cancer	2.65e-05	0.000109	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—hematologic cancer	2.65e-05	0.000109	CcSEcCtD
Deferoxamine—Pruritus—Prednisone—hematologic cancer	2.64e-05	0.000109	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—hematologic cancer	2.64e-05	0.000109	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—hematologic cancer	2.63e-05	0.000108	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—hematologic cancer	2.62e-05	0.000108	CcSEcCtD
Deferoxamine—XDH—Metabolism—ARNTL—hematologic cancer	2.61e-05	0.00309	CbGpPWpGaD
Deferoxamine—Dyspnoea—Epirubicin—hematologic cancer	2.61e-05	0.000107	CcSEcCtD
Deferoxamine—Diarrhoea—Prednisone—hematologic cancer	2.56e-05	0.000105	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—hematologic cancer	2.55e-05	0.000105	CcSEcCtD
Deferoxamine—Nausea—Betamethasone—hematologic cancer	2.55e-05	0.000105	CcSEcCtD
Deferoxamine—Nausea—Dexamethasone—hematologic cancer	2.55e-05	0.000105	CcSEcCtD
Deferoxamine—XDH—Metabolism—CA9—hematologic cancer	2.54e-05	0.00301	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ACP5—hematologic cancer	2.54e-05	0.00301	CbGpPWpGaD
Deferoxamine—Hypotension—Doxorubicin—hematologic cancer	2.53e-05	0.000104	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—hematologic cancer	2.52e-05	0.000104	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOR2—hematologic cancer	2.51e-05	0.00297	CbGpPWpGaD
Deferoxamine—Pain—Epirubicin—hematologic cancer	2.5e-05	0.000103	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—hematologic cancer	2.48e-05	0.000102	CcSEcCtD
Deferoxamine—Dizziness—Prednisone—hematologic cancer	2.47e-05	0.000102	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—hematologic cancer	2.47e-05	0.000102	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—hematologic cancer	2.47e-05	0.000102	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	2.46e-05	0.000102	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—hematologic cancer	2.43e-05	0.0001	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—hematologic cancer	2.41e-05	9.94e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—IDH1—hematologic cancer	2.39e-05	0.00283	CbGpPWpGaD
Deferoxamine—Gastrointestinal pain—Epirubicin—hematologic cancer	2.39e-05	9.85e-05	CcSEcCtD
Deferoxamine—Vomiting—Prednisone—hematologic cancer	2.38e-05	9.8e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—ABCC3—hematologic cancer	2.36e-05	0.0028	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTO1—hematologic cancer	2.36e-05	0.0028	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TXN—hematologic cancer	2.36e-05	0.0028	CbGpPWpGaD
Deferoxamine—Headache—Prednisone—hematologic cancer	2.34e-05	9.65e-05	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	2.33e-05	9.63e-05	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—hematologic cancer	2.32e-05	9.57e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—SPHK1—hematologic cancer	2.31e-05	0.00274	CbGpPWpGaD
Deferoxamine—Pain—Doxorubicin—hematologic cancer	2.31e-05	9.53e-05	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—hematologic cancer	2.31e-05	9.53e-05	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—hematologic cancer	2.31e-05	9.53e-05	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—hematologic cancer	2.3e-05	9.49e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—UGT1A1—hematologic cancer	2.22e-05	0.00263	CbGpPWpGaD
Deferoxamine—Nausea—Prednisone—hematologic cancer	2.22e-05	9.15e-05	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—hematologic cancer	2.21e-05	9.12e-05	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—hematologic cancer	2.21e-05	9.11e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—CRABP1—hematologic cancer	2.16e-05	0.00256	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—SLC22A1—hematologic cancer	2.16e-05	0.00256	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Epirubicin—hematologic cancer	2.15e-05	8.88e-05	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—hematologic cancer	2.15e-05	8.86e-05	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—hematologic cancer	2.14e-05	8.81e-05	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—hematologic cancer	2.14e-05	8.81e-05	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—hematologic cancer	2.14e-05	8.81e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—ALOX5—hematologic cancer	2.11e-05	0.00249	CbGpPWpGaD
Deferoxamine—Pruritus—Epirubicin—hematologic cancer	2.07e-05	8.53e-05	CcSEcCtD
Deferoxamine—Dizziness—Methotrexate—hematologic cancer	2.07e-05	8.51e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—NUP98—hematologic cancer	2.04e-05	0.00241	CbGpPWpGaD
Deferoxamine—Diarrhoea—Epirubicin—hematologic cancer	2e-05	8.24e-05	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—hematologic cancer	1.99e-05	8.21e-05	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—hematologic cancer	1.99e-05	8.19e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—ADCY7—hematologic cancer	1.98e-05	0.00234	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NCOA3—hematologic cancer	1.98e-05	0.00234	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NUP214—hematologic cancer	1.97e-05	0.00233	CbGpPWpGaD
Deferoxamine—Headache—Methotrexate—hematologic cancer	1.96e-05	8.07e-05	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—hematologic cancer	1.93e-05	7.97e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—ABCG2—hematologic cancer	1.93e-05	0.00228	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MTR—hematologic cancer	1.93e-05	0.00228	CbGpPWpGaD
Deferoxamine—Pruritus—Doxorubicin—hematologic cancer	1.91e-05	7.89e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—ENO2—hematologic cancer	1.89e-05	0.00224	CbGpPWpGaD
Deferoxamine—Vomiting—Epirubicin—hematologic cancer	1.86e-05	7.66e-05	CcSEcCtD
Deferoxamine—Nausea—Methotrexate—hematologic cancer	1.85e-05	7.65e-05	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—hematologic cancer	1.85e-05	7.63e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTT1—hematologic cancer	1.83e-05	0.00217	CbGpPWpGaD
Deferoxamine—Headache—Epirubicin—hematologic cancer	1.83e-05	7.55e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—SDC1—hematologic cancer	1.79e-05	0.00212	CbGpPWpGaD
Deferoxamine—Dizziness—Doxorubicin—hematologic cancer	1.79e-05	7.37e-05	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—hematologic cancer	1.74e-05	7.16e-05	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—hematologic cancer	1.72e-05	7.09e-05	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—hematologic cancer	1.69e-05	6.98e-05	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—hematologic cancer	1.61e-05	6.62e-05	CcSEcCtD
Deferoxamine—XDH—Metabolism—NQO1—hematologic cancer	1.52e-05	0.0018	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CD44—hematologic cancer	1.52e-05	0.0018	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYCS—hematologic cancer	1.44e-05	0.00171	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HSP90AA1—hematologic cancer	1.43e-05	0.00169	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTP1—hematologic cancer	1.27e-05	0.0015	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ABCB1—hematologic cancer	1.2e-05	0.00142	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NCOR1—hematologic cancer	1.17e-05	0.00138	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM1—hematologic cancer	1.17e-05	0.00138	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—MTHFR—hematologic cancer	1.03e-05	0.00122	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CG—hematologic cancer	8.67e-06	0.00103	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CREBBP—hematologic cancer	8.04e-06	0.000951	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CD—hematologic cancer	7.62e-06	0.000902	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ALB—hematologic cancer	7.53e-06	0.00089	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3R1—hematologic cancer	7.2e-06	0.000852	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CB—hematologic cancer	6.64e-06	0.000786	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTEN—hematologic cancer	5.74e-06	0.000679	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—EP300—hematologic cancer	5.48e-06	0.000648	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CA—hematologic cancer	4.05e-06	0.000479	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AKT1—hematologic cancer	3.31e-06	0.000391	CbGpPWpGaD
